10-Q: Avinger Inc. Reports Q3 2024 Results Amidst Strategic Realignment and Financial Restructuring

Avinger Inc. announced its Q3 2024 financial results, highlighting a strategic realignment and cost reduction plan, alongside ongoing efforts to secure financial stability.

Summary

• Avinger Inc. reported a net loss of $3.7 million for the third quarter of 2024, compared to a net loss of $4.5 million in the same period last year.
• The company's revenue for the quarter was $1.65 million, a decrease from $1.8 million in Q3 2023.
• Gross margin increased to 26% in Q3 2024 from 21% in Q3 2023, primarily due to decreased cost of revenues.
• Operating expenses decreased to $4.1 million from $4.4 million year-over-year.
• The company's accumulated deficit reached $434.3 million as of September 30, 2024.
• Avinger believes its cash and cash equivalents of $5.9 million, along with expected revenues and financing activities, will be sufficient to fund operations through the end of the fourth quarter of 2024.
• The company completed a public offering in June 2024, raising $6.0 million before expenses, and received $7.5 million from a private placement in March 2024.
• Avinger also entered into a strategic collaboration with Zylox-Tonbridge, including a licensing and distribution agreement for the Greater China region.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments like the strategic collaboration and improved gross margin, the significant revenue decline, ongoing losses, and going concern uncertainty weigh heavily on the overall sentiment. The need for further capital raises and the risk of delisting also contribute to a negative outlook.

Positives

• Gross margin improved to 26% in Q3 2024, up from 21% in the same period last year.
• Operating expenses decreased by 7.4% year-over-year.
• The company successfully raised $13.5 million through a private placement and public offering.
• Avinger secured a strategic collaboration with Zylox-Tonbridge, expanding its market reach.
• The company converted $11.0 million of debt into equity, improving its balance sheet.

Negatives

• Revenue decreased by 9% in Q3 2024 compared to Q3 2023.
• The company reported a net loss of $3.7 million for the quarter.
• Avinger has an accumulated deficit of $434.3 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company reduced its sales force by 33% as part of a strategic realignment.

Risks

• Avinger faces substantial doubt about its ability to continue as a going concern.
• The company needs to raise additional capital to fund operations and product development.
• There is a risk of delisting from the Nasdaq Capital Market if the company fails to maintain listing requirements.
• The company's debt obligations could be accelerated if a Material Adverse Change occurs.
• Avinger is dependent on a single financial institution for its cash and cash equivalents.
• The company's revenue is concentrated with a few key customers.
• The company is subject to risks associated with global supply chain disruptions and inflationary pressures.

Future Outlook

Avinger expects its cash and cash equivalents, along with expected revenues and financing activities, will be sufficient to fund operations through the end of the fourth quarter of 2024. The company anticipates needing to raise additional capital through future equity or debt financings to meet its operational needs and capital requirements for product development, clinical trials and commercialization.

Management Comments

• Management believes that its cash and cash equivalents, together with debt and other financing activities and expected revenues from operations, will be sufficient to allow the company to fund its current operations through the end of the fourth quarter of 2024.
• Management expects to incur losses for the foreseeable future.
• Management believes that the company's ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.

Industry Context

The medical device industry, particularly in the coronary and peripheral artery disease sectors, is highly competitive and marked by rapid technological advancements. Avinger's strategic collaboration with Zylox-Tonbridge and focus on next-generation products like Tigereye ST and Pantheris LV are attempts to maintain a competitive edge. However, the company faces challenges in a market with established players and evolving technologies.

Comparison to Industry Standards

• Avinger's revenue decline of 9% in Q3 2024 contrasts with some larger medical device companies that have reported stable or growing revenues in the same period, indicating potential market share challenges.
• The company's gross margin improvement to 26% is a positive sign, but it still lags behind some industry leaders that often achieve gross margins above 50%.
• Avinger's operating expenses, while reduced, remain high relative to its revenue, suggesting a need for further cost optimization.
• The company's reliance on external financing and its going concern status are not uncommon for early-stage medical device companies, but the level of uncertainty is higher than for more established competitors.
• Compared to companies like Medtronic or Abbott, Avinger's scale and financial resources are significantly smaller, making it more vulnerable to market fluctuations and competitive pressures.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional financing and the risk of delisting.
• Employees may experience uncertainty due to the company's cost reduction plan and potential future restructuring.
• Customers may be affected by potential supply chain disruptions and changes in the company's sales strategy.
• Creditors face the risk of non-payment or reduced recovery in the event of a bankruptcy filing.

Next Steps

• Avinger will continue to focus on driving catheter utilization in its strongest peripheral markets.
• The company will continue to develop its coronary product program.
• Avinger will seek additional financing through future equity or debt offerings.
• The company will work to maintain compliance with Nasdaq listing requirements.

Key Dates

Keywords

Avinger, Lumivascular, Pantheris, Ocelot, Tigereye, PAD, atherectomy, medical devices, financial results, strategic collaboration, capital raise, Nasdaq, going concern